Evidence map›Paper›PMID 28319080›Full record

ArticleBone marrow transplantation2017

Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

A P Nair, P Walker, A Kalff, K Bergin, J Hocking, S Avery, D J Curtis, S Patil, T Das, D Klarica and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

A P NairMalignant Haematology, Alfred Hospital, Melbourne, Australia.
P WalkerMalignant Haematology, Alfred Hospital, Melbourne, Australia.
A KalffMalignant Haematology, Alfred Hospital, Melbourne, Australia.
K BerginMalignant Haematology, Alfred Hospital, Melbourne, Australia.
J HockingMalignant Haematology, Alfred Hospital, Melbourne, Australia.
S AveryMalignant Haematology, Alfred Hospital, Melbourne, Australia.
D J CurtisMalignant Haematology, Alfred Hospital, Melbourne, Australia.
S PatilMalignant Haematology, Alfred Hospital, Melbourne, Australia.
T DasMalignant Haematology, Alfred Hospital, Melbourne, Australia.
D KlaricaMalignant Haematology, Alfred Hospital, Melbourne, Australia.
S MorganMalignant Haematology, Alfred Hospital, Melbourne, Australia.
J MuirheadMalignant Haematology, Alfred Hospital, Melbourne, Australia.
M GorniakMalignant Haematology, Alfred Hospital, Melbourne, Australia.
J ReynoldsAustralian Centre for Blood Diseases, Monash University, Melbourne, Australia.
A SpencerMalignant Haematology, Alfred Hospital, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-risk (HR) multiple myeloma (MM) has poor outcomes with conventional therapy. Tandem autologous-non-myeloablative (NMA) allogeneic stem cell transplantation (autologous stem cell transplantation (ASCT)-NMA allogeneic SCT) is potentially curative secondary to graft-versus-myeloma effect. We retrospectively analysed ASCT-NMA allogeneic SCT outcomes of 59 HR and relapsed MM patients. At a median follow-up of 35.8 months, the outcomes for HR-MM upfront tandem ASCT-NMA allogeneic SCT and standard-risk (SR) MM upfront ASCT alone were comparable (median PFS 1166 days versus 1465 days, P=0.36; median overall survival (OS) not reached in both cohorts, P=0.31). The 5-year PFS and OS of patients who had ASCT-NMA allogeneic SCT after relapsing from previous ASCT were 30% and 48% respectively. High CD3+ cell dose (>3 × 10

Indexed as

CD3 ComplexLymphocyte TransfusionStem Cell TransplantationAcute DiseaseAdultAgedAllograftsAutograftsChronic DiseaseDisease-Free SurvivalFemaleFollow-Up StudiesGraft vs Host DiseaseHumansMaleMiddle AgedCD3 Complex

Identifiers

PMID28319080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.